Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2024; 15(5): 576-579
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.576
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.576
Pembrolizumab autoimmune related diabetes: Moving forward, keep learning
Jose Angel Garcia, Diego Alcaraz, Department of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Madrid 28002, Spain
Esther Holgado, Department of Chief of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Madrid 28002, Spain
Felipe Couñago, Department of Chief of Radiation Oncology, Genesiscare-San Francisco de Asis University Hospital, Madrid 28002, Spain
Felipe Couñago, Department of Chief of Radiation Oncology, GenesisCare-Vithas La Milagrosa Hospital, Madrid 28010, Spain
Author contributions: Garcia JA, Alcaraz D, Holgado E and Couñago F contributed equally to this work; Garcia JA, Alcaraz D, Holgado E and Couñago F wrote the manuscript; All authors have read and approve the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jose Angel Garcia, MMed, Attending Doctor, Department of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Joaquin Costa 28, Madrid 28002, Spain. jose.garcia@genesiscare.es
Received: November 30, 2023
Revised: February 25, 2024
Accepted: April 8, 2024
Published online: May 24, 2024
Processing time: 172 Days and 22.2 Hours
Revised: February 25, 2024
Accepted: April 8, 2024
Published online: May 24, 2024
Processing time: 172 Days and 22.2 Hours
Core Tip
Core Tip: Pembrolizumab-induced type 1 diabetes mellitus is a rare and potentially serious adverse event of immunotherapy, with a significant number of cases debuting abruptly and in a state of diabetic ketoacidosis without clear predisposing factors. Further research and strict follow-up by oncologists are fundamental tools for prevention and early treatment focusing on reducing the morbidity and mortality associated with this side effect.